Company profile
BrightPath Biotherapeutics Co., Ltd.
4594 · TSE Growth (Verified via web search: listed on Tokyo Stock Exchange Growth Market under code 4594; developer of BP2202 iPSC-derived BCMA CAR-iNKT cell therapy for multiple myeloma. Sources: https://clinicaltrials.gov/study/NCT07667868 Entity resolved by asset-pipeline-v2.)
Public Market Listing
Live quotes, historical charts, and market capitalization for BrightPath Biotherapeutics Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | BCMABiologic — subtype unspecified | Multiple Myeloma |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.